Business
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline®, growing by 27.5% at CERStrong pipeline momentum with three Phase III readouts expected in H2 2026Confirmation of full-year 2026 guidance2 PARIS, FRANCE, 23 April 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026. Q1 2026% change€mActualCEROncology
About this update from Ipsen Sa
[{"type":"image","alt":"Ipsen Pharma","displaySize":"","headline":null,"caption":"Ipsen Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wakHirC7E7muNni_m7g_kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31","width":300,"height":157},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/wakHirC7E7muNni_m7g_kQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total sales growth of 22.6% at CER1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline®, growing by 27.5% at CER","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong pipeline momentum with three Phase III readouts expected in H2 2026","length":74,"tagName":"p"}]},{"val":[{"type":"text","content":"Confirmation of full-year 2026 guidance2","length":40,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":292,"olType":false},{"type":"text","content":"PARIS, FRANCE, 23 April 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026.","length":182,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"rowspan":"2","style":"width:139.87px;vertical-align:middle;","val":[{"type":"text","content":"","length":2,"tagName":"p","attribs":{}}]},{"style":"width:81px;text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Q1 2026","length":7,"tagName":"p","attribs":{}}]},{"colspan":"2","style":"width:134px;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"% change","length":8,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:81px;text-align:center;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"€m","length":2,"tagName":"p","attribs":{}}]},{"style":"width:67px;text-align:center;vertical-align:middle;vertical-align:middle;","val":[{"type":"text","content":"Actual","length":6,"ta...